Angstrom AI utilizes generative AI to perform molecular simulations that compute free energy differences, binding conformations, and hydration sites with ab initio accuracy. This technology replaces traditional wet lab experiments in pre-clinical drug development, significantly accelerating the research process and reducing costs.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional molecular simulations used in pre-clinical drug development are computationally expensive and time-consuming, often requiring extensive wet lab experiments for validation. This slows down the research process and increases costs associated with identifying promising drug candidates.
Solution
Angstrom AI offers a generative AI platform that accelerates molecular simulations, enabling accurate computation of free energy differences, binding conformations, and hydration sites. By leveraging advanced AI algorithms, the platform significantly reduces the reliance on traditional wet lab experiments, providing faster and more cost-effective insights into molecular behavior. This allows researchers to quickly identify and optimize potential drug candidates, streamlining the pre-clinical drug development pipeline. The platform's ab initio accuracy ensures reliable results, facilitating data-driven decision-making in drug discovery.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in pre-clinical drug development.
Features
- Generative AI models for predicting molecular properties with ab initio accuracy
- Computation of free energy differences, binding conformations, and hydration sites
- Orders-of-magnitude speedup compared to traditional molecular simulation methods
- Selected publications available for review, demonstrating scientific rigor